



## **Trellis Bioscience and PDL BioPharma Collaborate To Discover Novel Antibodies Using Trellis' Antibody CellSpot™ Technology**

**South San Francisco, CA (January 16, 2006):** Trellis Bioscience, Inc., a privately held biotechnology company, announced today a collaboration with PDL BioPharma, Inc. (Nasdaq:PDLI) to use Trellis proprietary CellSpot™ technology to discover monoclonal antibodies directed against a proprietary PDL antigen.

"There are many antigens to which specific, high-affinity monoclonal antibodies have been difficult or impossible to generate," stated Nolan H. Sigal, M.D., Ph.D., president of Trellis Bioscience. "Antibody CellSpot™ is a novel discovery platform that greatly enhances the odds of finding and retrieving the cells that are making desired antibodies but which are escaping detection through conventional discovery techniques due to their rarity."

Under the terms of the agreement, Trellis will use Antibody CellSpot™ to screen large populations of antibody-producing cells developed by the parties using a variety of immunization strategies. Trellis will select and deliver hybridomas to PDL BioPharma, which will conduct further research and development on the antibodies. PDL BioPharma will develop and commercialize any products discovered during the research collaboration, and Trellis will receive an upfront fee, milestone payments and royalties on products discovered in the collaboration.

### **About Trellis Bioscience**

Trellis Bioscience has developed a breakthrough technology platform for discovery and selection of very rare cells that produce ideal proteins such as antibodies, selected for specificity, selectivity, affinity, secretion rate and other desired characteristics. The company's proprietary CellSpot™ platform is at the convergence of nanotechnology, software, digital microscopy and biology and allows for a parallel evaluation of millions of cells simultaneously along more than 15 desired parameters in unprecedented detail. The technology has broad application in the discovery and production process development of therapeutic proteins. In addition to applying CellSpot™ to the discovery and manufacturing needs of partners, Trellis is developing a pipeline of native human antibodies for the treatment of infectious disease and oncology. More information about Trellis Bioscience can be found at [www.trellisbio.com](http://www.trellisbio.com).

###

### **CONTACTS:**

FOR TRELIS BIOSCIENCE:

Nolan Sigal  
(650) 616-1122  
[nsigal@trellisbio.com](mailto:nsigal@trellisbio.com)

Joan Kureczka  
Kureczka/Martin Associates:  
(415) 821-2413  
[jkureczka@comcast.net](mailto:jkureczka@comcast.net)